Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Go back to Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
(NASDAQ: DFTX) Delayed: 38.81 +0.13 (0.34%)
Previous Close $38.68    52 Week High
Open $38.67    52 Week Low
Day High $39.04    P/E N/A 
Day Low $38.10    EPS
Volume 3,215,135